MX391344B - Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). - Google Patents
Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).Info
- Publication number
- MX391344B MX391344B MX2019000694A MX2019000694A MX391344B MX 391344 B MX391344 B MX 391344B MX 2019000694 A MX2019000694 A MX 2019000694A MX 2019000694 A MX2019000694 A MX 2019000694A MX 391344 B MX391344 B MX 391344B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- toll
- inhibitors
- compounds
- tlr8
- Prior art date
Links
- 102100039390 Toll-like receptor 7 Human genes 0.000 title abstract 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 DIMETHOXYPHENYL-SUBSTITUTED INDOL COMPOUNDS Chemical class 0.000 title 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 title 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 title 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 title 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 title 1
- 102000002689 Toll-like receptor Human genes 0.000 title 1
- 108020000411 Toll-like receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 abstract 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611026137 | 2016-07-30 | ||
| PCT/US2017/044091 WO2018026620A1 (en) | 2016-07-30 | 2017-07-27 | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000694A MX2019000694A (es) | 2019-07-10 |
| MX391344B true MX391344B (es) | 2025-03-21 |
Family
ID=61073069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000694A MX391344B (es) | 2016-07-30 | 2017-07-27 | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11180474B2 (enExample) |
| EP (1) | EP3490983B1 (enExample) |
| JP (1) | JP6995109B2 (enExample) |
| KR (1) | KR102506321B1 (enExample) |
| CN (1) | CN109715617B (enExample) |
| AU (1) | AU2017307208B2 (enExample) |
| BR (1) | BR112019001270A2 (enExample) |
| CA (1) | CA3031675A1 (enExample) |
| EA (1) | EA038972B1 (enExample) |
| ES (1) | ES2863474T3 (enExample) |
| IL (1) | IL264462B (enExample) |
| MX (1) | MX391344B (enExample) |
| SG (1) | SG11201900619XA (enExample) |
| WO (1) | WO2018026620A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| EA038972B1 (ru) | 2016-07-30 | 2021-11-16 | Бристол-Маерс Сквибб Компани | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 |
| MA46188A (fr) | 2016-09-09 | 2019-07-17 | Bristol Myers Squibb Co | Composés indole substitués par pyridyle |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| ES2921020T3 (es) * | 2017-08-04 | 2022-08-16 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
| ES2909401T3 (es) | 2017-08-04 | 2022-05-06 | Bristol Myers Squibb Co | Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9 |
| US20210253593A1 (en) | 2017-11-14 | 2021-08-19 | Bristol-Myers Squibb Company | Substituted indole compounds |
| EP3717467A1 (en) * | 2017-12-01 | 2020-10-07 | Taiwanj Pharmaceuticals Co., Ltd. | Benzene fused heterocyclic compound and use thereof |
| MX2020006093A (es) | 2017-12-15 | 2020-08-24 | Bristol Myers Squibb Co | Compuestos de indol eter sustituidos. |
| PE20210129A1 (es) | 2017-12-18 | 2021-01-19 | Bristol Myers Squibb Co | Compuestos de 4-azaindol |
| BR112020011788A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | compostos 6-azaindóis |
| CN111491930B (zh) * | 2017-12-19 | 2023-09-26 | 百时美施贵宝公司 | 可用作tlr抑制剂的经取代的吲哚化合物 |
| ES2922174T3 (es) | 2017-12-19 | 2022-09-09 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con amida útiles como inhibidores de TLR |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7291707B2 (ja) | 2017-12-20 | 2023-06-15 | ブリストル－マイヤーズ スクイブ カンパニー | アリールおよびヘテロアリール置換されたインドール化合物 |
| US11299501B2 (en) | 2017-12-20 | 2022-04-12 | Bristol-Myers Squibb Company | Diazaindole compounds |
| KR102714788B1 (ko) * | 2017-12-20 | 2024-10-08 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr 억제제로서 유용한 아미노 인돌 화합물 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| JP7374130B2 (ja) | 2018-06-05 | 2023-11-06 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物 |
| CN112313228A (zh) | 2018-06-12 | 2021-02-02 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物 |
| CN112584903B (zh) | 2018-07-23 | 2025-12-23 | 豪夫迈·罗氏有限公司 | 用于自身免疫性疾病治疗的哌嗪化合物 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| EP3847170B1 (en) | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| WO2020048596A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| EP3870589B1 (en) * | 2018-10-24 | 2023-09-06 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
| KR102839382B1 (ko) * | 2018-10-24 | 2025-07-25 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 및 인다졸 화합물 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3965888B1 (en) * | 2019-05-09 | 2024-08-21 | Bristol-Myers Squibb Company | Substituted benzimidazolone compounds |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| WO2021067326A1 (en) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| ES2965164T3 (es) | 2019-10-04 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de carbazol sustituidos |
| EP4051387B1 (en) * | 2019-10-31 | 2025-02-19 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| US12486273B2 (en) | 2019-11-19 | 2025-12-02 | Hoffmann-La Roche Inc. | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| EP4061821B1 (en) | 2019-11-20 | 2025-08-06 | F. Hoffmann-La Roche AG | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| CN116075510A (zh) | 2020-08-19 | 2023-05-05 | 百时美施贵宝公司 | 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化 |
| IL300727A (en) | 2020-08-19 | 2023-04-01 | Bristol Myers Squibb Co | Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis |
| US20250002471A1 (en) * | 2020-12-22 | 2025-01-02 | Gilead Sciences, Inc. | 6-substituted indole compounds |
| WO2022140326A1 (en) * | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | Substituted indole compounds |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| TWI849499B (zh) | 2021-09-10 | 2024-07-21 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| CN118754873B (zh) * | 2024-06-27 | 2025-03-07 | 广东医科大学 | 一种环丁烷吲哚衍生物及其制备方法和应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU779117B2 (en) | 1998-12-18 | 2005-01-06 | Axys Pharmaceuticals, Inc. | Protease inhibitors |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| WO2006113458A1 (en) * | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
| JP2009532501A (ja) | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス， インコーポレイテッド | 疾患および障害のための化合物 |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| WO2008065198A1 (en) | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| WO2010036905A1 (en) | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| CA2738929A1 (en) | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| TR201809739T4 (tr) | 2009-07-16 | 2018-07-23 | Mallinckrodt Llc | Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları. |
| WO2012054862A2 (en) | 2010-10-21 | 2012-04-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritis and related skin conditions |
| BR112013017947A2 (pt) | 2011-01-12 | 2018-12-18 | Array Biopharma Inc | benzoazepinas substituídas como moduladores de receptor toll-like |
| MX346387B (es) | 2011-01-12 | 2017-03-02 | Ventirx Pharmaceuticals Inc | Benzoazepinas sustituidas como moduladores de receptores tipo toll. |
| ES2583877T3 (es) | 2011-06-01 | 2016-09-22 | Janus Biotherapeutics, Inc. | Moduladores novedosos del sistema inmunitario |
| CA2837227C (en) | 2011-06-01 | 2022-05-10 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| ES2602813T3 (es) * | 2011-06-09 | 2017-02-22 | Rhizen Pharmaceuticals S.A. | Nuevos compuestos como moduladores de GPR-119 |
| AU2012285931B2 (en) | 2011-07-15 | 2017-01-12 | Cellzome Limited | Novel substituted indole derivatives as gamma secretase modulators |
| US9873694B2 (en) | 2011-10-04 | 2018-01-23 | Janus Biotherapeutics, Inc. | Imidazole quinoline-based immune system modulators |
| AU2013261267B2 (en) | 2012-05-18 | 2017-06-29 | Sumitomo Pharma Co., Ltd. | Carboxylic acid compounds |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| EP3626717A1 (en) | 2013-10-14 | 2020-03-25 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| CA2933466A1 (en) | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| CN107108629A (zh) | 2014-08-22 | 2017-08-29 | 贾纳斯生物治疗有限公司 | 新颖的n2, n4, n7, 6‑四取代的蝶啶‑2,4,7‑三胺和2, 4, 6, 7‑四取代的蝶啶化合物及其合成和使用方法 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| EA038972B1 (ru) | 2016-07-30 | 2021-11-16 | Бристол-Маерс Сквибб Компани | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 |
| MA46188A (fr) | 2016-09-09 | 2019-07-17 | Bristol Myers Squibb Co | Composés indole substitués par pyridyle |
-
2017
- 2017-07-27 EA EA201990169A patent/EA038972B1/ru unknown
- 2017-07-27 ES ES17764925T patent/ES2863474T3/es active Active
- 2017-07-27 CN CN201780058063.4A patent/CN109715617B/zh active Active
- 2017-07-27 SG SG11201900619XA patent/SG11201900619XA/en unknown
- 2017-07-27 MX MX2019000694A patent/MX391344B/es unknown
- 2017-07-27 WO PCT/US2017/044091 patent/WO2018026620A1/en not_active Ceased
- 2017-07-27 BR BR112019001270-2A patent/BR112019001270A2/pt not_active IP Right Cessation
- 2017-07-27 KR KR1020197005484A patent/KR102506321B1/ko active Active
- 2017-07-27 CA CA3031675A patent/CA3031675A1/en active Pending
- 2017-07-27 EP EP17764925.8A patent/EP3490983B1/en active Active
- 2017-07-27 US US16/321,616 patent/US11180474B2/en active Active
- 2017-07-27 AU AU2017307208A patent/AU2017307208B2/en not_active Ceased
- 2017-07-27 JP JP2019504954A patent/JP6995109B2/ja active Active
-
2019
- 2019-01-24 IL IL264462A patent/IL264462B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019000694A (es) | 2019-07-10 |
| CN109715617A (zh) | 2019-05-03 |
| KR102506321B1 (ko) | 2023-03-03 |
| IL264462B (en) | 2021-12-01 |
| AU2017307208B2 (en) | 2021-01-21 |
| EP3490983B1 (en) | 2021-02-17 |
| EA038972B1 (ru) | 2021-11-16 |
| CN109715617B (zh) | 2022-04-19 |
| EP3490983A1 (en) | 2019-06-05 |
| AU2017307208A1 (en) | 2019-03-14 |
| BR112019001270A2 (pt) | 2019-04-30 |
| KR20190034264A (ko) | 2019-04-01 |
| ES2863474T3 (es) | 2021-10-11 |
| US20210292300A1 (en) | 2021-09-23 |
| EA201990169A1 (ru) | 2019-07-31 |
| JP2019525941A (ja) | 2019-09-12 |
| WO2018026620A1 (en) | 2018-02-08 |
| SG11201900619XA (en) | 2019-02-27 |
| JP6995109B2 (ja) | 2022-01-14 |
| US11180474B2 (en) | 2021-11-23 |
| CA3031675A1 (en) | 2018-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391344B (es) | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). | |
| MX2020005462A (es) | Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr). | |
| MX2020005515A (es) | Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr). | |
| MX2020006168A (es) | Compuestos de 4-azaindol. | |
| MX2020005513A (es) | Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr). | |
| MX2020005622A (es) | Compuestos de indol sustituidos con arilo y heteroarilo. | |
| MX2020005873A (es) | Compuestos de 6-azaindol. | |
| MX2020006093A (es) | Compuestos de indol eter sustituidos. | |
| MX2020006014A (es) | Compuestos de diazaindol. | |
| MY196474A (en) | [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds | |
| MX382383B (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo toll | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| CR20200312A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| MX390698B (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| MX382727B (es) | Derivado de benzazepina, método de preparación, composición farmacéutica y su uso | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| BR112013017943A2 (pt) | benzoazepinas substituídas como moduladores receptores do tipo toll | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| MX376481B (es) | Compuestos de pirazol y su uso como bloqueadores de canales de calcio tipo t. | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| MX373162B (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
| MX2017011434A (es) | Compuestos heterociclicos triciclicos sustituidos. |